natgillin/translations-raw huggingface dataset:
A maximum blood concentration of 0.8 ng/ml was measured in only 2 patients in week 6 of treatment.
Najvišja krvna koncentracija 0, 8 ng/ ml je bila izmerjena samo pri 2 bolnikih med 6. tednom zdravljenja.
In 8 adult atopic dermatitis patients, in which AUC levels could be quantified, the AUC (0-12h) values ranged from 2.5 to 11.4 ng h/ml.
Pri 8 odraslih bolnikih z atopijskim dermatitisom, pri katerih je bilo možno izračunati AUC, so vrednosti AUC( 0- 12h) segale od 2, 5 do 11, 4 ng h/ ml.
Absorption in children Systemic exposure to pimecrolimus was investigated in 58 paediatric patients aged 3 months to 14 years.
Absorpcija pri otrocih Sistemska izpostavljenost pimekrolimusu je bila raziskana pri 58 pediatričnih bolnikih, starih od 3 mesecev do 14 let.
The affected BSA ranged from 10-92%.
Prizadeta BSA je bila od 10- 92%.
These children were treated with < Invented Name > twice daily for 3 weeks and five out of them were treated for up to 1 year on a “as needed” basis.
Večina otrok je bila zdravljena z {Lastniško ime} dvakrat na dan 3 tedne, pet otrok pa po načelu “ po potrebi ” do 1 leta.
18 Pimecrolimus blood concentrations were consistently low regardless of the extent of lesions treated or duration of therapy.
Koncentracije pimekrolimusa v krvi so bile stalno nizke, ne glede na obseg zdravljenih lezij ali trajanje zdravljenja.
Around 60% of pimecrolimus blood concentrations were below 0.5 ng/ml and 97% of all samples were below 2 ng/ml.
Okrog 60% koncentracij pimekrolimusa v krvi je bilo nižjih od 0, 5 ng/ ml, 97% vseh vzorcev pa je bilo pod 2 ng/ ml.
The highest blood concentrations measured in 2 paediatric patients aged 8 months to 14 years were 2.0 ng/ml.
Najvišja koncentracija v krvi, izmerjena pri 2 pediatričnih bolnikih, starih od 8 mesecev do 14 let, je bila 2, 0 ng/ ml.
In infants (aged 3 to 23 months), the highest blood concentration measured in one patient was 2.6 ng/ml.
Pri najmlajših bolnikih (starih od 3 do 23 mesecev) je bila najvišja koncentracija v krvi, izmerjena pri enem bolniku, 2, 6 ng/ ml.
In the 5 children treated for 1 year, blood concentrations were consistently low (maximum blood concentration was 1.94 ng/ml in 1 patient).
Pri 5 otrocih, zdravljenih 1 leto, so bile koncentracije v krvi stalno nizke (najvišja izmerjena koncentracija v krvi je bila 1, 94 ng/ ml pri 1 bolniku).
There was no increase in blood concentration over time in any patient during the 12 months of treatment.
Pri nobenem od bolnikov koncentracija v krvi v 12 mesecih zdravljenja ni sčasoma naraščala.
In 8 paediatric patients aged 2-14 years, AUC (0-12h) ranged from 5.4 to 18.8 ng h/ml.
Pri 8 pediatričnih bolnikih, starih 2– 14 let, so vrednosti AUC( 0- 12h) segale od 5, 4 do 18, 8 ng h/ ml.
AUC ranges observed in patients with < 40% BSA affected at baseline were comparable to those in patients with ≥40% BSA.
Razponi AUC pri bolnikih, ki so imeli v izhodišču prizadete < 40% BSA, so bili primerljivi s tistimi pri bolnikih z ≥40% BSA.
The maximum body surface area treated was 92% in clinical pharmacology studies and up to 100% in Phase III trials.
18 Največja zdravljena telesna površina je bila 92% v kliničnofarmakoloških raziskavah in do 100% v preizkusih III faze.
Distribution, Metabolism, and Excretion Consistent with its skin selectivity, after topical application, pimecrolimus blood levels are very low.
Porazdelitev, presnova in izločanje V skladu s selektivnostjo pimekrolimusa za kožo po lokalni uporabi so njegove koncentracije v krvi zelo nizke.
After single oral administration of radiolabeled pimecrolimus in healthy subjects, unchanged pimecrolimus was the major active substance-related component in blood and there were numerous minor metabolites of moderate polarity that appeared to be products of O-demethylations and oxygenation.
Po eni sami peroralni aplikaciji radioaktivno označenega pimekrolimusa zdravim osebam je bil nespremenjeni pimekrolimus poglavitna z učinkovino povezana sestavina v krvi, bili pa so še številni manj pomembni presnovki zmerne polarnosti, za katere se je izkazalo, da so produkti O- demetilacij in oksigenacije.
Active substance-related radioactivity was excreted principally via the faeces (78.4%) and only a small fraction (2.5%) was recovered in urine.
Z učinkovino povezana radioaktivnost se je izločala predvsem z blatom (78, 4%) in le majhen delež (2, 5%) je bil prestrežen v urinu.
Total mean recovery of radioactivity was 80.9%.
Celotni povprečni prestrezek radioaktivnosti je bil 80, 9%.
Effects on reproductive organs and altered sex hormone functions were seen in male and female rats in repeated dose toxicity studies after oral administration of 10 or 40 mg/kg/day (= 20 to 60 times the maximum human exposure after dermal application).
Pri raziskavah toksičnosti ponavljajočih se odmerkov po peroralni uporabi 10 ali 40 mg/ kg/ dan (= 20 do 60 kratna največja izpostavljenost pri človeku po uporabi na koži) so bili ugotovljeni učinki na spolne organe in spremenjeno delovanje spolnih hormonov pri podganjih samcih in samicah.
The No Observed Adverse Effect Level (NOAEL) for female fertility was 10 mg/kg/day (= 20 times the maximum human exposure after dermal application).
Raven, pri kateri niso bili opaženi nikakršni neugodni učinki (NOAEL) za plodnost pri samicah, je bila 10 mg/ kg/ dan (= 20 kratna največja izpostavljenost pri človeku po uporabi na koži).
In the oral embryotoxicity study in rabbits, a higher resorption rate associated with maternal toxicity was observed at 20 mg/kg/day (= 7 times the maximum human exposure after dermal application); the mean number of live fetuses was not affected.
Zdravilo ni vplivalo na povprečno število živih plodov.
Dose-dependent increases in the incidence of lymphomas were observed at all doses in a 39 week monkey oral toxicity study.
V 39- tedenski študiji peroralne toksičnosti pri opicah so opazili od odmerka odvisno povečanje incidence limfomov pri vseh odmerkih.
Signs of recovery and/or at least partial reversibility of the effects were noted upon cessation of dosages in a few animals.
Pri nekaterih živalih so opazili znake okrevanja in/ ali vsaj delne reverzibilnosti učinkov po prenehanju dajanja zdravila.
Failure to derive a NOAEL precludes an assessment of the margin of safety between a non-carcinogenic concentration in the monkey and exposures in patients.
Ker niso mogli ugotoviti NOAEL, niso mogli oceniti varnostne meje med ne- karcinogenimi koncentracijami pri opicah in izpostavljenostjo pri bolnikih.
The risk for humans cannot be completely ruled
Sistemska izpostavljenost koncentraciji LOAEL 15 mg/ kg/ dan je bila 31 krat večja od najvišje izpostavljenost pri človeku nasploh (pri pediatričnem bolniku).
19 out as the potential for local immunosuppression with the long-term use of pimecrolimus cream is unknown.
Tveganja za človeka ni mogogče popolnoma izključiti, ker ni znano, kakšna je možnost lokalne imunosupresije ob dolgotrajni uporabi pimekrolimusa.
Medium chain triglycerides Oleyl alcohol Propylene glycol Stearyl alcohol Cetyl alcohol Mono-and di-glycerides Sodium cetostearyl sulphate Benzyl alcohol Citric acid anhydrous Sodium hydroxide Purified water
19 monogliceridi in digliceridi, natrijev cetilsulfat in stearilsulfat, benzilalkohol, brezvodna citronska kislina, natrijev hidroksid, prečiščena voda
After first opening the container:
Po prvem odpiranju tube:
12 months.
12 mesecev.
Aluminium tube with a phenol-epoxy protective inner lacquer and polypropylene screw cap.
Aluminijasta tuba z notranjim zaščitnim fenol- epoksi lakom in s polipropilenskim pokrovčkom z navojem.
6.6 Instructions for use and handling
6. 6 Navodila za uporabo in ravnanje z zdravilom
Emollients can be applied together with < Invented Name > (see Section 4.2 “Posology and method of administration”).
Emolienti se lahko uporabljajo skupaj z {Lastniško ime} (glejte poglavje 4. 2 “ Odmerjanje in način uporabe ”).
< < Date of revision > >
{Datum zadnje revizije}
21 LABELLING AND PACKAGE LEAFLET
21 OZNAČEVANJE
22 LABELLING
22 PODATKI NA ZUNANJI OVOJNINI
{NATURE/TYPE}
{VRSTA/ TIP}
< {(Invented) name strength pharmaceutical form} >
< Lastniško ime > 1% krema
< {(Invented) name and associated names (see Annex I) strength pharmaceutical form} > < [See Annex I - To be completed nationally] > [For referral procedures]
< {(Lastniško) ime in povezana imena (glejte Dodatek I) jakost farmacevtska oblika} > < [Glejte Dodatek I – Izpolni država članica] >
Pimecrolimus
pimekrolimus
STATEMENT OF ACTIVE SUBSTANCE(S)
1 g kreme vsebuje 10 mg pimekrolimusa.
Medium chain triglycerides, Oleyl alcohol, Propylene glycol, Stearyl alcohol, Cetyl alcohol, Mono- and di-glycerides, Sodium cetostearyl sulphate, Benzyl alcohol, Citric acid anhydrous, Sodium hydroxide, Purified water
srednjeverižni trigliceridi, oleilalkohol, propilenglikol, stearilalkohol, cetilalkohol, monogliceridi in digliceridi, natrijev cetilsulfat in stearilsulfat, benzilalkohol, brezvodna citronska kislina, natrijev hidroksid, prečiščena voda
1% Cream
krema
Read the package leaflet before use.
za dermalno uporabo Pred uporabo preberite priloženo navodilo.
8.
15.
EXPIRY DATE [For terms on Batch number and Expiry date see Appendix IV]
Nanesite tanko plast < Lastniško ime > in popolnoma prekrijte prizadeto kožo.
24 9.
24 PODATKI, KI MORAJO BITI NAJMANJ NAVEDENI NA MANJŠIH STIČNIH OVOJNINAH
SPECIAL STORAGE CONDITIONS [For storage conditions statements see Appendix III]
IME ZDRAVILA IN POT( I) UPORABE
< [To be completed nationally] > [For referral procedures, as appropriate]
< Lastniško ime > 1% krema pimekrolimus
SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE
Pred uporabo preberite priloženo navodilo.
NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER
DATUM IZTEKA ROKA UPORABNOSTI ZDRAVILA
< [To be completed nationally] > < [See Annex I - To be completed nationally] > [For referral procedures]
{MM/ LLLL}
{Name and Address} < {tel} > < {fax} > < {e-mail} >
ŠTEVILKA SERIJE
12.
Lot:
MARKETING AUTHORISATION NUMBER(S)
VSEBINA, IZRAŽENA Z MASO, PROSTORNINO ALI ŠTEVILOM ENOT
< [To be completed nationally] >
[Ustrezno izpolni država članica]
BATCH NUMBER [For terms on Batch number and Expiry date see Appendix IV]
POSEBNO OPOZORILO O SHRANJEVANJU ZDRAVILA ZUNAJ DOSEGA IN POGLEDA OTROK
GENERAL CLASSIFICATION FOR SUPPLY
Zdravilo shranjujte nedosegljivo otrokom.
< [To be completed nationally] >
POSEBNA NAVODILA ZA SHRANJEVANJE
< Medicinal product subject to medical prescription. > < Medicinal product not subject to medical prescription. >
Ne zamrzujte.
INSTRUCTIONS ON USE
[Izpolni država članica]
Apply a thin layer of < Invented Name > and completely cover the affected skin.
{Ime in naslov} < {tel.} > < {fax} > < {e- mail} >
INFORMATION IN BRAILLE
ŠTEVILKA DOVOLJENJA ZA PROMET
< [To be completed nationally] > [For referral procedures]
[Izpolni država članica]
25 PACKAGE LEAFLET
25 NAVODILO ZA UPORABO
< {(Invented) name and associated names (see Annex I) strength pharmaceutical form} > < [See Annex I - To be completed nationally] > [For referral procedures]
< Lastniško ime > 1% krema < {(Lastniško) ime in povezana imena (glejte Dodatek I) jakost farmacevtska oblika} > < [Glejte Dodatek I – Izpolni država članica] >
Read all of this leaflet carefully before you start using < Invented Name > cream
Pred začetkom uporabe kreme < Lastniško ime > natančno preberite navodilo.
may harm them, even if their symptoms are the same as yours
škodovalo, čeprav imajo znake bolezni, podobne vašim.
What < Invented Name > cream is and what it is used for 2.
Kaj je zdravilo < Lastniško ime > krema in za kaj jo uporabljamo 2.
Before you use < Invented Name > cream 3.
Kaj morate vedeti, preden boste uporabili kremo < Lastniško ime > 3.
How to apply < Invented Name > cream 4.
Kako uporabljati kremo < Lastniško ime > 4.
Storing < Invented Name > cream 6.
Shranjevanje kreme < Lastniško ime > 6.
WHAT < INVENTED NAME > CREAM IS AND WHAT IT IS USED FOR
KAJ JE ZDRAVILO < LASTNIŠKO IME > KREMA IN ZA KAJ JO UPORABLJAMO
< Invented Name > cream is a white, odourless, non-staining and easily spreadable cream containing 1% by weight pimecrolimus.
< Lastniško ime > je bela krema brez vonja, ki ne pušča madežev, se z lahkoto razmaže in vsebuje 1% pimekrolimusa (masni delež).
< Invented Name > cream specifically treats an inflammation of the skin called atopic dermatitis (eczema).
Krema < Lastniško ime > je posebej namenjena zdravljenju vnetja kože, ki ga imenujemo atopijski dermatitis (ekcem).
It works in the cells in the skin that cause the inflammation and characteristic redness and itching of eczema. < Invented Name > cream is available in tubes of 15 g, 30 g, 60 g and 100 g.
Krema < Lastniško ime > je na voljo v tubah po 15 g, 30 g, 60 g in 100 g.
The cream is used to treat signs and symptoms of mild or moderate eczema (e.g. redness and itch) in children (aged 2 years and above), teenagers and adults When used to treat early signs and symptoms it can prevent progression to severe flare-ups.
Če se uporabi za zdravljenje zgodnjih znakov in simptomov, lahko prepreči napredovanje bolezni do hudih izbruhov.
< Invented Name > Cream is for use only after other prescription medicines or emollients have not worked for you or if your Doctor recommends that other prescription medicines should not be used.
Kremo < Lastniško ime > se uporablja samo, če druga zdravila na recept ali negovalne kreme niso dovolj učinkovite ali če vam zdravnik odsvetuje uporabo drugih krem na recept.
BEFORE YOU USE < INVENTED NAME > CREAM
KAJ MORATE VEDETI, PREDEN BOSTE UPORABILI KREMO < LASTNIŠKO IME >
Read the following information before you use < Invented Name > cream.
Preden uporabite < Lastniško ime >, preberite naslednje informacije.
Do not use < Invented Name > cream
Ne uporabljajte kreme < Lastniško ime >:
- If you are hypersensitive (allergic) to pimecrolimus or any of the other ingredients of
- če ste alergični na (preobčutljivi za) pimekrolimus ali katerokoli sestavino kreme < Lastniško
< Invented Name > cream.
ime >;
- If you have a weakened immune system (you are immuno-compromised)
- če je vaš imunski sistem oslabljen (ste imunokompromitirani).
27 Take special care with < Invented Name > cream
27 Bodite posebno pozorni pri uporabi kreme < Lastniško ime > Krema < Lastniško ime > ni odobrena za uporabo pri otrocih, ki so mlajši od 2 let.
< Invented Name > is not approved for children younger than 2 years of age.
Krema < Lastniško ime > se sme uporabljati samo za atopijski dermatitis.
Therefore it should not be used in this age group.
Ne uporabljajte je za druge spremembe na koži.
< Invented Name > Cream is only to be used for atopic dermatitis.
Krema < Lastniško ime > je namenjen samo za zunanjo uporabo.
Do not use for other skin conditions. < Invented Name > cream is for external use only.
Ne nanašajte je v nos, oči ali usta.
Do not use it in your nose, eyes or mouth.
Če kremo nehote nanesete na te predele, jo morate temeljito obrisati in/ ali sprati z vodo.
If accidentally applied to these areas, the cream should be thoroughly wiped off and/or rinsed with water.
Pazite, da kreme ne bi zaužili ali je nehote prenesli v usta, kadar jo naprimer nanašate na roke.
You should take care not to swallow it, or to accidentally transfer it into your mouth when for example it is applied to the hands.
Kreme ne nanašajte na tiste predele kože, ki so prizadeti zaradi aktivne virusne okužbe, kot sta herpes (herpes simpleks) ali vodene koze (norice).
Do not apply the cream to areas of the skin affected by active viral infection such as cold sores (herpes simplex) or chicken pox.
Če imate na koži okužbo, vam bo zdravnik svetoval ustrezno zdravilo za zdravljenje okužbe.
If your skin is infected, your doctor may ask you to use an appropriate medicine to treat the infection.
Šele ko se okužba na prizadetih mestih pozdravi, se lahko začne zdravljenje z < Lastniško ime >.
When the infection at treatment sites is cleared, treatment with < Invented Name > can be started.
Če pride do okužbe kože med zdravljenjem z < Lastniško ime >, morate na to opozoriti zdravnika.
If your skin becomes infected during treatment with < Invented Name >, you should inform your doctor.
Zdravnik vam bo morda svetoval, da prekinete z uporabo < Lastniško ime >, dokler se okužba ne pozdravi dovolj.
Your doctor may ask you to stop using < Invented Name > until the infection has been adequately controlled. < Invented Name > may be associated with an increased risk of a severe herpes simplex skin infection (eczema herpeticum).
Zato takoj opozorite zdravnika, če opazite boleče rane na koži kjerkoli po telesu.
Therefore if you develop painful sores anywhere on your body, tell your doctor immediately.
Zdravljenje z < Lastniško ime > je treba prekiniti, dokler se okužba ne pozdravi.
Treatment with < Invented Name > should be discontinued until the infection has cleared. < Invented Name > may cause reactions at the application site such as a feeling of warmth and/or a burning sensation.
< Lastniško ime > lahko na mestu uporabe povzroča reakcije, kot sta občutek toplote in/ ali pečenja.
Tell your doctor immediately if you have a severe reaction to < Invented Name >.
Če pride do hude reakcije na < Lastniško ime >, takoj opozorite zdravnika.
If you are using < Invented Name >, do not cover the treated skin with bandages, dressings or wraps.
Če uporabljate < Lastniško ime >, ne pokrivajte kože z obvezami ali s povoji.
If you are outdoors after applying < Invented Name >, wear loose fitting clothing, use appropriate sunscreen products and minimise the amount of time you spend in the sun.
Med zdravljenjem z < Lastniško ime > se izogibajte prekomernemu izpostavljanju sončni svetlobi, ultravijoličnim svetilkam in sončenju v solariju.
If you have erythroderma (redness of almost the entire body) or a skin condition called Netherton’s syndrome, speak to your doctor before you start using < Invented Name >.
Če boste po nanosu < Lastniško ime > na prostem, si oblecite ohlapna oblačila, uporabite primerno zaščitno kremo za sončenje in se kar najmanj zadržujte na soncu.
Also speak to your doctor before using < Invented Name > if you have any skin malignancies (tumours) or if you have a weakened immune system (immuno-compromised) whatever the cause.
Če imate eritrodermijo (rdečo kožo po skoraj celem telesu) ali kožno bolezen, ki se imenuje Nethertonov sindrom, se posvetujte z zdravnikom preden začnete uporabljati < Lastniško ime >.
Pregnancy and breast-feeding
Prav tako se pred uporabo < Lastniško ime > posvetujte z zdravnikom v primeru, da imate na koži malignom (kožnega raka) ali oslabljen imunski sistem iz kateregakoli razloga (ste imunokompromitirani).
Tell your doctor before starting treatment with < Invented Name > if you are pregnant or think that you may be pregnant.
Nosečnost in dojenje Preden začnete zdravljenje z < Lastniško ime >, povejte zdravniku, če ste noseči ali menite, da bi lahko bili.
You should not use < Invented Name > if you are pregnant.
Če ste noseči, < Lastniško ime > ne smete uporabljati.
Tell your doctor if you are breast-feeding before using < Invented Name > or any other medicines.
Če dojite, opozorite na to zdravnika preden uporabite < Lastniško ime > ali katerokoli drugo zdravilo.
It is not known whether the active substance in < Invented Name > passes into the milk after application to the skin.
Ni znano, ali zdravilna učinkovina v < Lastniško ime > po nanosu na kožo prehaja v materino mleko.
Do not apply < Invented Name > to the breasts if breast-feeding.
Če dojite, < Lastniško ime > ne nanašajte na dojke.
< Invented Name > has no known effect on the ability to drive or use machines.
Vpliv na sposobnost upravljanja vozil in strojev Ni znano, da bi < Lastniško ime > vplival na sposobnost upravljanja vozil in strojev.
Using other medicines
Uporaba drugih zdravil Obvestite svojega zdravnika ali farmacevta, če jemljete ali ste pred kratkim jemali katerokoli zdravilo, tudi če ste ga dobili brez recepta.
Inform your doctor or pharmacist if you are taking or have recently taken any other medicines, even those not prescribed by a doctor.
Vaš zdravnik vam po povedal, če bo to potrebno.
If you have extensive eczema, treatment with < Invented Name > may have to be stopped before any vaccinations.
< Lastniško ime > se ne sme uporabljati hkrati z zdravljenjem z ultravijolično svetlobo (npr.
Your doctor will be able to tell you if this is necessary. < Invented Name > should not be used at the same time as ultraviolet light treatments (e.g.
UVA, PUVA, UVB) ali sistemskimi zdravili, ki zavirajo imunsko odzivnost (sistemskimi imunosupresivi, kot sta azatioprin ali ciklosporin).
28 Interactions with other medicines that you take are unlikely to occur.
Medsebojno delovanje z drugimi zdravili, ki jih jemljete, je malo verjetno.
HOW TO APPLY < INVENTED NAME > CREAM
KAKO UPORABLJATI KREMO < LASTNIŠKO IME >
Always use < Invented Name > exactly as your doctor has instructed.
Pri uporabi kreme < Lastniško ime > vedno natančno upoštevajte zdravnikova navodila.
Please check with your doctor or pharmacist if you have any questions.
Če ste negotovi, se posvetujte z zdravnikom ali s farmacevtom.
You can use < Invented Name > on all skin areas, including the head, face and neck and in the folds of the skin.
< Lastniško ime > lahko uporabljate na vseh predelih kože, tudi na glavi, po obrazu in v kožnih pregibih.
• Wash and dry your hands. • Open the tube (the first time you use the tube you will need to break the seal using the spike in the top of the cap). • Squeeze the cream onto your finger. • Apply a thin layer of < Invented Name > and completely cover the affected skin. • Apply only on areas affected with eczema • Rub in gently and fully. • Replace the cap on the tube.
(Pred prvo uporabo boste morali preluknjati zaščitno zaporko s konico, ki je na vrhu pokrovčka). • Iztisnite nekaj kreme na prst. • Nanesite tanko plast < Lastniško ime > in povsem prekrijte prizadeto kožo. • Nanašajte samo na predele z ekcemom. • Kremo nežno in temeljito vtrite v kožo. • Tubo zaprite s pokrovčkom.
You can use moisturisers (emollients) with < Invented Name >.
Skupaj z < Lastniško ime > lahko uporabljate sredstva za vlaženje kože (emoliente).
If you use moisturisers, they should be applied immediately after < Invented Name >.
Če uporabljate sredstva za vlaženje kože, jih je treba nanašati takoj po nanosu < Lastniško ime >.
Do not bath, shower or swim right after applying < Invented Name >.
Takoj po mazanju z < Lastniško ime > se ne prhajte ali kopajte in ne plavajte.
How long to apply < Invented Name >
Kako dolgo uporabljati kremo < Lastniško ime >
Stop < Invented Name > as soon as signs of eczema have disappeared.
Pri dolgotrajnem zdravljenju uporabljajte kremo s presledki (intermitentno) in ne neprekinjeno. < Lastniško ime > prenehajte uporabljati takoj, ko znaki ekcema izginejo.
In the long-term treatment of eczema, begin using < Invented Name > as soon as you notice signs and symptoms (redness and itch).
Pri dolgotrajnem zdravljenju ekcema, začnite uporabljati < Lastniško ime > takoj, ko opazite znake in simptome (rdečino in srbenje).
If you apply more < Invented Name > than you should
Če ste uporabili večji odmerek kreme < Lastniško ime >, kot bi smeli Če nanesete na kožo več kreme, kot bi bilo treba, jo samo obrišite.
If you forget an application of the cream, apply it as soon as possible and then continue your normal dosing routine.
Če ste pozabili uporabiti kremo < Lastniško ime > Če se pozabite namazati s kremo, jo nanesite čimprej in nato nadaljujte z običajnim urnikom uporabe.
If you accidentally swallow some < Invented Name > If you or someone else accidentally swallows < Invented Name >, tell your doctor immediately.
Če nehote zaužijete nekaj kreme < Lastniško ime > Če vi ali kdo drug nehote zaužije < Lastniško ime >, takoj obvestite zdravnika.
The most common side effects of < Invented Name > are reactions (e.g. discomfort) at the application site.
Najbolj pogosti neželeni učinki < Lastniško ime > so reakcije (npr. neprijeten občutek) na mestu uporabe.
Such reactions are generally mild/moderate, occur early in treatment and last only for a short time.
Take reakcije so na splošno blage/ zmerne, pojavijo se zgodaj v poteku zdravljenja in trajajo le kratek čas.